Поиск по репозиторию
Статья
Treatment of patients with COVID-19 and concomitant cardiovascular diseases: Do not Forget about the Principles of Evidence-based Medicine [Лечение больных с COVID-19 и сопутствующими сердечно-сосудистыми заболеваниями: не забывать о принципах доказательной медицины]
2021
The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article. There is controversy over the hypothesis that these drugs can be factors contributing to an unfavorable outcome of a viral disease, as well as the absence of any clinical evidence for this hypothesis. The opinion that withdrawal of ACE inhibitors and ARA in patients with COVID-19 may increase the risk of adverse outcomes is presented. © 2020 Stolichnaya Izdatelskaya Kompaniya. All rights reserved.
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- Rational Pharmacotherapy in Cardiology
Том
- 16
Выпуск
- 2
Страницы
- 273-276
Ключевые слова
- angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; adverse outcome; Article; cardiovascular disease; clinical outcome; coronavirus disease 2019; drug withdrawal; evidence based medicine; human
Издатель
- Stolichnaya Izdatelskaya Kompaniya
Тип документа
- journal article
Тип лицензии Creative Commons
- CC
Правовой статус документа
- Свободная лицензия
Источник
- scopus
